Brachytherapy for cervix cancer: Low-dose rate or high-dose rate brachytherapy - A meta-analysis of clinical trials

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Viani, Gustavo A ^a   Manta, Gustavo B ^a   Stefano, Eduardo J ^a   De Fendi, Ligia I ^a  

^a Marilia Medical School   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIBLIOGRAPHIC DATABASE; BRACHYTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCERLIT; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; FEMALE; MORTALITY; PATHOLOGY; RADIATION RESPONSE; RECURRENT DISEASE; UTERINE CERVIX TUMOR;

BRACHYTHERAPY; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; NEOPLASM STAGING; RECURRENCE; UTERINE CERVICAL NEOPLASMS;

EID: 65349096704     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-47     Document Type: Article

References (49)

1. Dose and volume specifications for reporting intracavitary therapy in gynecology. International Commission on Radiation Units and Measurements (ICRU), Bethesda, MD: ICRU 1985
2. The American Brachytherapy Society Survey of brachytherapy practice for carcinoma of the cervix in the United States. S Nag C Orton D Young, Gyn Oncol 1999 73 111 118 10.1006/gyno.1998.5334 (Pubitemid 29177609)
3. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study. PJ Eifel J Moughan B Erickson T Iarocci D Grant J Owen, Int J Radiat Oncol Biol Phys 2004 60 1144 1153 15519786 (Pubitemid 39440800)
4. Clinical applications of brachytherapy II. A Martinez JA Stitt BL Speiser, Principles and practice of radiation oncology Philadelphia: Lippincott-Raven, Perez CA, Brady LW, 3 1997 569 580
5. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison System. I. Clinical and radiobiological considerations. JA Stitt JF Fowler BR Thomadsen, Int J Radiat Oncol Biol Phys 1992 24 335 348 1526873
6. Resource utilization: High dose rate versus low dose rate brachytherapy for gynecologic cancer. KT Bastin DA Buchler JA Stitt, Am J Clin Oncol 1993 16 256 263 10.1097/00000421-199306000-00013 8338060
7. Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix. J Wright G Jones T Whelan, Radiother Oncol 1994 33 187 194 10.1016/0167-8140(94)90353-0 7716259
8. High-dose-rate intracavitary irradiation in the treatment of carcinoma of the uterine cervix: early experience with 84 patients. Y Akine H Arimoto T Ogino Y Kajiura I Tsukiyama S Egawa, Int J Radiat Oncol Biol Phys 1988 14 893 8 3360656 (Pubitemid 18135108)
9. High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix. T Arai T Nakano S Morita K Sakashita YK Nakamura K Fukuhisa, Cancer 1992 69 175 80 10.1002/1097-0142(19920101)69:1<175::AID- CNCR2820690129>3.0.CO;2-B 1727661
10. The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix. BG Clark L Souhami TN Roman R Chappell MD Evans JF Fowler, Int J Radiat Oncol Biol Phys 1997 38 989 93 9276363 (Pubitemid 27353677)
11. Comparison of HDR afterloading with 192Ir versus conventional radium therapy in cervix cancer: 5-year results and complications. FH Glaser, Sonderb Strahlenther Onkol 1988 82 106 13 3134704
12. Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy. KS Kapp GF Stuecklschweiger DS Kapp J Poschauko H Pickel A Hackl, Radiother Oncol 1997 42 143 53 10.1016/S0167-8140(96)01881-6 9106923 (Pubitemid 27132743)
13. A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma. JN Sarkaria DG Petereit JA Stitt T Hartman R Chappell BR Thomadsen, Int J Radiat Oncol Biol Phys 1994 30 75 82 discussion, 247 8083131 (Pubitemid 24291116)
14. 5-year results with HDR afterloading in cervix cancer: dependence on fractionation and dose. H Vahrson G Romer, Sonderb Strahlenther Onkol 1988 82 139 46 3393979
15. Current controversies inhigh-dose-rate versus low-dose-rate brachytherapy for cervicalcancer. AJ Stewart AN Viswanathan, Cancer 2006 1; 107 5 908 15 10.1002/cncr.22054 (Pubitemid 44291138)
16. Statistical aspects of the analysis of data from retrospective studies of disease. N Mantel W Haenszel, J Natl Cancer Inst 1959 22 719 748 13655060
17. Meta-analysis in clinical trials. R DerSimonian N Laird, Control Clin Trials 1986 7 177 188 10.1016/0197-2456(86)90046-2 3802833 (Pubitemid 17189972)
18. Measuring inconsistency in meta-analysis. JPT Higgins SG Thompson JJ Deeks DG Altman, BMJ 2003 327 557 560 12958120 10.1136/bmj.327.7414.557
19. JPT Higgins S Green Eds, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration 2008
20. rating quality of evidence and strength of recommendations: grade: what is "quality of evidence" and why is it important to clinicians? GH Guyatt AD Oxman GE Vist R Kunz Y Falck-Ytter hj Schunemann, BMJ 2008 336 7651 995 998 18456631 10.1136/bmj.39490.551019.BE
21. The combination of estimates from differentexperiments. WG Cochran, Biometrics 1954 8 101 129 10.2307/3001666
22. High-dose-rate versus low-dose-rate intracavitarytherapy for carcinoma of the uterine cervix: a randomized trial. M Hareyama K Sakata A Oouchi H Nagakura M Shido M Someya K Koito, Cancer 2002 1; 94 1 117 24 10.1002/cncr.10207 (Pubitemid 34049049)
23. Lowdose rate vs. high dose rate brachytherapy in the treatment ofcarcinoma of the uterine cervix: a clinical trial. FD Patel SC Sharma PS Negi S Ghoshal BD Gupta, Int J Radiat Oncol Biol Phys 1994 15; 28 2 335 41 (Pubitemid 24020516)
24. High-dose rate and low-doserate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. T Teshima T Inoue H Ikeda Y Miyata K Nishiyama T Inoue S Murayama H Yamasaki T Kozuka, Cancer 1993 15; 72 8 2409 14 10.1002/1097-0142(19931015)72:8<2409::AID- CNCR2820720819>3.0.CO;2-N (Pubitemid 23299606)
25. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. P Lertsanguansinchai C Lertbutsayanukul K Shotelersuk C Khorprasert P Rojpornpradit T Chottetanaprasith A Srisuthep S Suriyapee C Jumpangern D Tresukosol C Charoonsantikul, Int J Radiat Oncol Biol Phys 2004 59 5 1424 1431 15275728 (Pubitemid 38954064)
26. Comparing Low-Dose-Rate andHigh-Dose-Rate Intracavitary Brachytherapy in Carcinoma Cervix: Results From a Randomized Controlled Study. S Shrivastava K Dinshaw U Mahantshetty R Engineer N Patil D Deshpande H Tongaonkar, Int J Radiat Oncol Biol Phys 2006 1; 66 3 S42
27. Cancer statistics, 2008. A Jemal R Siegel E Ward, CA Cancer J Clin 2008 58 71 10.3322/CA.2007.0010 18287387
28. Cervical cancer, human papillomavirus, and vaccination. CM Lowndes ON Gill, BMJ 2005 331 915 916 16239668 10.1136/bmj.331.7522.915 (Pubitemid 41510841)
29. Global Cancer Statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
30. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. S Nag B Erickson B Thomadsen, Int J Rad Oncol Biol Phys 2000 48 201 221 10.1016/S0360-3016(00)00497-1 (Pubitemid 30488231)
31. Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis. AW Fyles M Pintilie P Kirkbridge, Radiother Oncol 1995 35 107 117 10.1016/0167-8140(95)01535-O 7569018
32. Carcinoma of the intact uterine cervix treated with radiotherapy alone: A French Cooperative Study: Update and multivariate analysis of prognostic factors. I Barillot JC Horiot J Pigneaux, Int J Radiat Oncol Biol Phys 1997 38 969 978 9276361 (Pubitemid 27353675)
33. Radiation alone in the treatment of cancer of the uterine cervix: Analysis of pelvic failure and dose response relationship. RY Kim A Trotti CJ Wu, Int J Radiat Oncol Biol Phys 1989 17 973 991 2808059 (Pubitemid 19279500)
34. Tumor and treatment factors improving outcome in staging IIIB cervix cancer. RM Lanciano KL Martz LR Coia, Int J Radiat Oncol Biol Phys 1991 20 95 108 1993635
35. Carcinoma of the cervix, stage III: Results of radiation therapy. GS Montana WC Fowler MA Varia, Cancer 1986 57 148 154 10.1002/1097-0142(19860101) 57:1<148::AID-CNCR2820570130>3.0.CO;2-7 3940615 (Pubitemid 16212251)
36. FIGO stage IIIB squamous cellcarcinoma of the uterine cervix: Natural history, treatment results, and prognostic factors. PJ Eifel MD Logsdon, Int J Radiat Oncol Biol Phys 1996 36 Suppl 217 10.1016/S0360-3016(97)85459-4
37. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series. R Ferrigno IN Nishimoto PE Novaes AC Pellizzon MA Maia RC Fogarolli JV Salvajoli, Int J Radiat Oncol Biol Phys 2005 62 4 1108 16 15990016 (Pubitemid 40884425)
38. Maximum and mean bladder dose defined from ultrasonography: Comparison with the ICRU reference in gynaecological brachytherapy. I Barillot JC Horiot P Maingon, Radiother Oncol 1994 30 231 238 10.1016/0167-8140(94)90463-4 8209007 (Pubitemid 24107517)
39. Comparison of radiography- and computed tomography-based treatment plan in cervix cancer in brachytherapy with specific attention to some quality assurance aspects. C Fellner R Potter TH Knocke, Radiother Oncol 2001 58 53 62 10.1016/S0167-8140(00)00282-6 11165682 (Pubitemid 32124794)
40. Carcinoma of the uterine cervix: A 3D-CT analysis of dose to the internal, external, and common iliac nodes in tandem and ovoid applications. WJ Gebara KJ Weeks EL Jones, Radiother Oncol 2000 50 43 48 10.1016/S0167-8140(00) 00176-6 (Pubitemid 30408385)
41. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. C Haie-Meder R Potter E Van Limbergen, Radiother Oncol 2005 74 235 245 10.1016/j.radonc.2004. 12.015 15763303 (Pubitemid 40349132)
42. Physiologic FDG-PET three-dimensional brachytherapy treatment plan for cervical cancer. RS Malyapa S Mutic DA Low, Int J Radiat Oncol Biol Phys 2002 54 1140 1146 10.1016/S0360-3016(02)03043-2 12419441 (Pubitemid 35292626)
43. Magnetic resonance imaging during intracavitary gynecologic brachytherapy. SL Schoeppel JH Ellis ML LaVigne, Int J Radiat Oncol Biol Phys 1992 23 169 174 1572813
44. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: Results of a prospective comparative trial. N Wachter-Gerstner S Wachter E Reinstadler, Radiother Oncol 2003 68 51 59 10.1016/S0167-8140(03)00083-5 12885452 (Pubitemid 37289336)
45. PET-guided three dimensional treatment planning of intracavitary gynecologic implants. S Mutic PW Grigsby DA Low, Int J Radiat Oncol Biol Phys 2002 52 1104 1110 11958908 (Pubitemid 34219033)
46. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. CE Pelloski M Palmer GM Chronowski, Int J Radiat Oncol Biol Phys 2005 62 131 137 10.1016/j.ijrobp.2004. 09.059 15850913 (Pubitemid 40591934)
47. Physics and dosimetry of high doserate brachytherapy. CG Orton GA Ezzell, Principles and practice of radiation oncology Philadelphia: Lippincott-Raven, Perez C, Brady L, 1997 473 92
48. High-dose-rate brachytherapy for carcinoma of the cervix: high tech or high risk? [editorial; comment] [see comments]. PJ Eifel, Int J Radiat Oncol Biol Phys 1992 24 383 6 1526879
49. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. CG Orton M Seyedsadr S Somnay, Int J Radiat Oncol Biol Phys 1991 21 1425 34 1938550